Antihypertensive medication use and incident breast cancer in women
- 303 Downloads
The purpose of this study was to evaluate whether antihypertensive medication use, including long-term use, is associated with increased breast cancer incidence in women. We studied 210,641 U.S. registered nurses participating in the Nurses’ Health Study (NHS) and Nurses’ Health Study II (NHS II). Information on antihypertensive medication use was collected on biennial questionnaires in both cohorts, and breast cancer cases were ascertained during this period. Multivariable-adjusted Cox proportional hazard models were used to estimate relative risks of invasive breast cancer over follow-up (1988–2012 in NHS, 1989–2011 in NHS II) across categories of overall antihypertensive medication use and use of specific classes (diuretics, beta blockers, calcium channel blockers, and angiotensin-converting enzyme inhibitors). During follow-up, 10,012 cases of invasive breast cancer developed (6718 cases in NHS and 3294 in the NHS II). Overall, current use of any antihypertensive medication was not associated with breast cancer risk compared with past/never use in NHS (multivariable-adjusted relative risk = 1.00, 95 % CI = 0.95–1.06) or NHS II (multivariable-adjusted relative risk = 0.94, 95 % CI = 0.86–1.03). Furthermore, no specific class of antihypertensive medication was consistently associated with breast cancer risk. Results were similar when we considered hypertensive women only, and when we evaluated consistency and duration of medication use over time. Overall, antihypertensive medication use was largely unrelated to the risk of invasive breast cancer among women in the NHS cohorts.
KeywordsAntihypertensive medication Breast cancer Cohort study Epidemiology
Nurses’ Health Study
- NHS II
Nurses’ Health Study II
We would like to thank the participants and staff of the Nurses’ Health Study and Nurses’ Health Study II for their valuable contributions, as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. We also want to acknowledge the contribution of Dr. Steven Lockley, Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women’s Hospital. He provided the initial impetus for examining associations between beta blocker use and breast cancer risk in women, based on his interest in the melatonin-modulating effects of beta blockers. Dr. Lockley did not receive any compensation for his contribution.
The National Cancer Institute funds the Nurses’ Health Study (P01 CA87969) and Nurses’ Health Study II (UM1 CA176726). L.R.W. received partial support from a National Institutes of Health training grant (R25 CA098566) during the time that she contributed to this paper.
Conflict of interest
The authors declare that they have no conflict of interest.
Statement on research involving human participants and/or animals
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
Implied informed consent, indicated by voluntary return of the cohort questionnaires, was obtained from all individual participants included in the study.
- 1.Carson AP, Howard G, Burke GL, Shea S, Levitan EB, Muntner P (2011) Ethnic differences in hypertension incidence among middle-aged and older adults: the multi-ethnic study of atherosclerosis. Hypertension 57(6):1101–1107. doi: 10.1161/HYPERTENSIONAHA.110.168005 CrossRefPubMedCentralPubMedGoogle Scholar
- 2.Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289(19):2560–2572. doi: 10.1001/jama.289.19.2560 CrossRefPubMedGoogle Scholar
- 3.Group USCSW (2013) United States Cancer Statistics: 1999-2010 Incidence and mortality web-based report. Atlanta, GAGoogle Scholar
- 5.Jick H, Jick SS, Myers MW, Vasilakis C (1997) Third-generation oral contraceptives and venous thrombosis. Lancet 349(9053):731–732; author reply 732–733. doi: 10.1016/S0140-6736(05)60173-0
- 20.Largent JA, Bernstein L, Horn-Ross PL, Marshall SF, Neuhausen S, Reynolds P, Ursin G, Zell JA, Ziogas A, Anton-Culver H (2010) Hypertension, antihypertensive medication use, and breast cancer risk in the California Teachers Study cohort. Cancer Causes Control 21(10):1615–1624. doi: 10.1007/s10552-010-9590-x CrossRefPubMedCentralPubMedGoogle Scholar
- 23.Colditz GA (1995) The nurses’ health study: a cohort of US women followed since 1976. J Am Med Women’s Assoc 50(2):40–44Google Scholar
- 26.Fung TT, Chiuve SE, Willett WC, Hankinson SE, Hu FB, Holmes MD (2013) Intake of specific fruits and vegetables in relation to risk of estrogen receptor-negative breast cancer among postmenopausal women. Breast Cancer Res Treat 138(3):925–930. doi: 10.1007/s10549-013-2484-3 CrossRefPubMedCentralPubMedGoogle Scholar
- 28.Holmes MD, Hankinson SE, Feskanich D, Chen WY (2013) Beta blockers and angiotensin-converting enzyme inhibitors’ purported benefit on breast cancer survival may be explained by aspirin use. Breast Cancer Res Treat 139(2):507–513. doi: 10.1007/s10549-013-2553-7 CrossRefPubMedCentralPubMedGoogle Scholar